Clinical trial

Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

NCT04358237

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Lurbinectedin Normalized identity: lurbinectedinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-09-21

PhasePHASE1 / PHASE2

Conditions

Small Cell Lung Carcinomaverified · MONDO: small cell lung carcinoma

Interventions

LurbinectedinDRUG · verified · RxNorm: lurbinectedin

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Antonio Calles Blancolead sponsor

MedSIRcollaborator

PharmaMarcollaborator

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

MadridSpain3 BarcelonaSpain2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04358237 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.